Moxifloxacin Krka

Moxifloxacin, the active ingredient in Moxifloxacin Krka, is a fluoroquinolone presented as an oral tablet for oral use. It treats a range of bacterial infections in adults, including pneumonia, sinusitis, bronchitis exacerbations, and skin infections. GNH USA supplies Moxifloxacin Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum antibacterial indicated for several respiratory and skin infections. - Community‑acquired bacterial pneumonia: effective treatment of infection caused by susceptible organisms in adults. - Acute bacterial sinusitis: resolves sinus inflammation due to susceptible bacteria. - Acute bacterial exacerbation of chronic bronchitis: shortens duration and severity of bacterial flare‑ups. - Skin and skin structure infections: eradicates susceptible pathogens in cellulitis, abscesses and wound infections.

Moxifloxacin may cause a range of adverse reactions, most of which are dose‑independent and related to its fluoroquinolone class.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional sense of light‑headedness. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, often linked to sudden activity. - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe hypersensitivity: including anaphylaxis or Stevens‑Johnson syndrome. - Central nervous system effects: seizures or psychosis in susceptible individuals.

Before prescribing Moxifloxacin, clinicians should assess patient‑specific risk factors and monitor for known safety concerns. - Renal impairment: adjust therapy if significant kidney dysfunction is present. - Hepatic disease: use with caution in patients with liver dysfunction. - Cardiac risk: avoid in patients with known QT prolongation or concurrent QT‑prolonging drugs. - Tendon disorders: advise patients to report tendon pain or swelling promptly. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Moxifloxacin can alter the plasma concentrations of several co‑administered medicines, requiring careful review of the patient’s medication list.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - NSAIDs (e.g., ibuprofen, naproxen): increase risk of central nervous system stimulation and seizures. - QT‑prolonging agents (e.g., quinidine, sotalol): may cause additive cardiac conduction delays.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: potential increase in serum theophylline levels, watch for toxicity. - Corticosteroids: may raise the risk of tendon rupture, advise caution.